Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

Christopher J. Sweeney, Bruce J. Roth, Fairooz F. Kabbinavar, David J. Vaughn, Michael Arning, Rafael E. Curiel, Coleman K. Obasaju, Yanping Wang, Steven J. Nicol, Donald S. Kaufman

Research output: Contribution to journalArticlepeer-review

211 Scopus citations

Abstract

Purpose: To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Patients and Methods: Eligible patients had a performance status of 0 or 1, adequate organ function, previous treatment with one prior chemotherapy regimen for locally advanced or metastatic TCC of the urothelium or relapsed within 1 year of adjuvant or neoadjuvant treatment. Patients received pemetrexed 500 mg/m2 intravenously on day 1 every 21 days, with vitamin B12, folic acid, and dexamethasone prophylaxis. Results: Forty-seven patients were enrolled and included in the intent-to-treat efficacy analysis. Responses: 3 (6.4%) complete responses and 10 (21.3%) partial responses produced an overall response rate of 27.7%. Ten patients (21.3%) had stable disease and 22 patients (46.8%) progressed. The median time to progressive disease was 2.9 months (95% CI, 1.7 months to 4.6 months) and median overall survival was 9.6 months (95% CI, 5.1 months to 14.6 months). Median duration of response was 5.0 months (95% CI, 3.9 months to 13.8 months). Of the 47 patients assessable for safety, grade 3 or 4 hematologic events were thrombocytopenia (8.5%; 0.0%), neutropenia (4.3%; 4.3%) and anemia (2.1%; 2.1%), respectively. Nonlaboratory toxicities included grade 4 stomatitis/pharyngitis, sepsis syndrome (one patient each), and grade 3 fatigue (three patients) and diarrhea (two patients). Conclusion: Single-agent pemetrexed is safe and active as second-line treatment of patients with advanced TCC of the urothelium. Additional evaluation in the first- or second-line setting in TCC of the urothelium is warranted.

Original languageEnglish
Pages (from-to)3451-3457
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number21
DOIs
StatePublished - Jul 20 2006

Fingerprint

Dive into the research topics of 'Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium'. Together they form a unique fingerprint.

Cite this